Eiko Lifesciences Ltd

Financial highlights

• Consolidated revenue from operations: ₹5,257.14 lakhs; up 39.6% YoY.
• Standalone revenue from operations: ₹4,212.68 lakhs; up 29.65% YoY.
• Consolidated PAT: ₹532.47 lakhs; up 129.7% YoY.
• Standalone PAT: ₹358.11 lakhs; up 105.7% YoY.
• Standalone EBITDA margin: 11.19%.
• Basic EPS: Consolidated ₹3.26; Standalone ₹2.60.
• Dividend declared for FY2025-26: none.

Growth & strategic moves

• Strategic acquisition: 51% stake in SSM Formulations Private Limited for ~₹18.15 crore.
• Entry into pharmaceutical formulations expands value chain beyond chemicals.
• Sumukh Vartak appointed Whole-Time Director.
• Logistics and R&D platforms expanded via EikoVivify and Eiko Scientific Solutions.
• Warrants and equity shares issued to promoters and public; funds to be used for growth.
• Escrow account opened with Bank of India to receive warrant proceeds.

Capital & capital structure

• Start-of-year equity capital ₹13.725 crore; end-of-year ₹14.3459 crore after allotments.
• Issued 6,25,000 equity shares at ₹55 each; 29,50,000 warrants issued.
• ₹405.62 lakh received against warrants; 25% received on application.
• Authorised capital increased to ₹20 crore.
• End-year outstanding warrants: 26,45,000.
• 3,05,000 equity shares allotted on warrant conversion.

Dividends & capital allocation

• Final dividend not declared for FY2025-26.
• Profits retained in P&L; no transfer to reserves.
• Funds from preferential issue to be used for acquisitions and general corporate purposes.
• Escrow arrangements for warrant proceeds established with Bank of India.

Subsidiaries & associates

• Subsidiaries: Eiko Vivify Logistics Private Limited; Eiko Scientific Solutions LLP.
• Associates: Reflux Pharmaceuticals Private Limited (25.01%); SSM Formulations Private Limited (31.67%).
• Material unlisted subsidiary: Eiko Vivify Logistics.
• Consolidation: equity method for associates.

Governance & audit

• Board comprises 6 directors; Suraj Mahadev Gaikwad appointed Independent Director.
• Sumukh Prabhakar Vartak designated Whole-Time Director; Hasti Doshi resigned.
• Statutory auditors PSV Jain & Associates; Secretarial auditors Shravan A. Gupta & Associates.
• Internal audit by NP Rajput & Co; no adverse observations.
• Related party transactions reviewed by Audit Committee; omnibus approvals in place.

Outlook & AGM

• Outlook: APIs and pharma forms growth driven by China+1 and regulatory shifts.
• Risks: raw material volatility, environmental compliance, currency, and supply chain.
• 49th AGM scheduled 22 September 2026 via VC/OAVM.
• Remote e-voting period 19-21 September 2026; AGM joining details on company site.

AGM Details

• Date and time: 22 September 2026, 04:00 PM IST; held via VC/OAVM.

Ordinary business resolutions

• Adopt audited standalone and consolidated financial statements for FY2025-26.
• Re-appoint Bhavesh Dhirajlal Tanna as Director, liable to retire by rotation.

Special business resolutions

• Appoint Suraj Mahadev Gaikwad as Independent Director for 5 years.
• Approve related party contracts/transactions with related parties on arm's length terms.

Material related party transactions

• Loans/advances between promoter/directors and company up to ₹5 crore each.
• Loans/advances by Bhavesh D Tanna up to ₹5 crore.
• Lake City Traders Private Limited—loans up to ₹5 crore.
• Lenus Finvest Private Limited—loans up to ₹5 crore.
• Plutus Capital Management LLP—loans up to ₹5 crore.
• Centrum Finserve (Partnership Firm)—loans up to ₹5 crore.
• Pharmaceuticals Private Limited—sales/purchases up to ₹50 crores.
• Jaid Kojar (CFO)—salary up to ₹15 Lakhs.
• Chintan Doshi (Company Secretary)—salary up to ₹3.5 Lakhs.
• Vivify Wealth Management LLP—loans up to ₹2 Crores.
• EikoVivify Logistics Pvt. Ltd.—subsidiary; intercompany advances up to ₹50 Crores.
• Eiko Scientific Solutions LLP—subsidiary; rent/loans up to ₹50 Crores.
• SSM Formulations Pvt. Ltd.—sales/purchases up to ₹50 Crores.
• Hercules Industries (Partnership Firm)—loans up to ₹20 crores.
• Promoter group entities will not vote on the related party resolution.
• Materiality threshold: 10% of turnover or ₹1,000 crore, whichever is lower.
• Board recommends the ordinary resolution for approval.

Resignation details

• Name and designation: Hasti Doshi, Independent Director.
• Effective date of resignation: 24 August 2026.
• Reason for resignation: other career commitments.
• No other material reasons for resignation disclosed.
• Resignation letter attached as Annexure I.
• No other listed entities where the director holds directorships or committee memberships.

Appointment of Independent Director

• Appointment of Mr. Suraj Mahadev Gaikwad as Additional Independent and Non-Executive Director, effective 24 August 2026.
• To hold office until the ensuing AGM, then for five years, subject to shareholder approval.
• Profile: Commerce graduate; 7+ years in accounting and business management.
• Disclosures: No related-party relationships with current directors.
• Notes: Appointment subject to shareholders' approval.
• Term details: Initial term up to AGM; thereafter 5-year independent director term.

Key Decisions

• Resigned: Ms. Hasti Doshi as Independent Director, effective 24 August 2026.
• Appointed Suraj Gaikwad as Additional Director (Independent/Non-Executive) on 24 Aug 2026 for 5-year term post-AGM.
• Recommended re-appointment of Bhavesh Dhirajlal Tanna as Director liable to retire by rotation.
• AGM for FY2025-26 scheduled for 22 September 2026 at 04:00 PM via VC.
• Notice for the 49th AGM approved for 22 September 2026 at 04:00 PM via VC.
• Appointed Shravan Gupta as Scrutinizer for e-voting and AGM.
• Appointed M/s Bigshare Services Pvt Ltd for e-voting and AGM video-conferencing.

IDBI recovery claim

• IDBI Bank alleges a ₹58 lakh corporate guarantee issued by Narendra Investments (Delhi) Limited in 1986.
• Company disputes the claim and has not admitted liability.
• Has taken legal steps and is pursuing all available remedies.
• Management does not expect material financial impact on operations.
• Will continue to monitor and disclose as required.

Financial results and approvals

• Approved standalone and consolidated unaudited quarterly results for quarter ended 30 June 2026, with Limited Review Report.
• Consolidated results report two segments: Speciality & Fine Chemicals and Logistics Services.
• Independent auditor's review found no material misstatement in standalone and consolidated results.